You are here

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: What’s hot that the other lot got
Free

https://doi.org/10.1136/thoraxjnl-2015-207694corr1

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Higginson J. What’s hot that the other lot got. Thorax 2015;70:1010.

This Journal club article was originally published with 2 citations missing. The relevant citations have been added to the text below. The editors would like to apologise for any inconvenience caused.

Beyond: first-line carboplatin/paclitaxel plus Bevacizumab or placebo in Chinese patients with advanced or recurrent non-squamous non-small-cell lung cancer

Zhou et al (J Clin Oncol 2015 Jul 1;33(19):2197–204) have performed a randomised, double-blind, multicentre, placebo-controlled, phase III study of first-line bevacizumab plus carboplatin/paclitaxel (B+CP) vs placebo plus carboplatin/paclitaxel (Pl+CP) in China where the epidermal growth factor receptor (EGFR) prevalence is 30%. Progression-free survival (PFS) was significantly prolonged in the B+CP arm compared with Pl+CP: 9.2 months (95% CI 8.4 to 10.7) vs 6.5 months (95% CI 5.8 to 7.1), respectively. In the EGFR-positive group, the median PFS was 12.4 months with B+CP and 7.9 months with Pl+CP (HR 0.27; 95% CI 0.12 to 0.63); PFS was 8.3 and 5.6 months (HR 0.33; 95% CI 0.21 to 0.53) in wild-type tumours.

Reliable Egfr Mutation testing in ultrasound-guided Supraclavicular lymph node fine-needle Aspirates

‘Not enough tissue for EGFR testing’ is a phrase commonly heard in lung cancer multidisciplinary team meetings. Awwad et al (BMJ Open Respiratory Research 2015;2:e000075. doi: 10.1136/bmjresp-2014–0 00 075) have retrospectively assessed all ultrasound (US)-guided fine needle aspiration (FNA) of neck node procedures performed in Nottingham University Hospital from 2001 to 2013. The procedures were carried out by a radiologist with a 21-gauge needle; the average short axis of sampled nodes was 12.9 mm and 41% of nodes were<10 mm. A total of 228 patients underwent FNA, and 57 were adenocarcinoma; 34 were tested for EGFR (EGFR testing was not routine at that time), and 29 (80%) of those samples were sufficient. The authors conclude that US-guided neck FNA is a reliable procedure for diagnosis of lung cancer including EGFR mutation testing.

Linked Articles